認知症・アルツハイマー病治療市場- 世界の産業規模、動向、機会、予測：薬剤クラス別、流通チャネル別、地域別セグメント、競合、2020年～2030年

認知症・アルツハイマー病治療の世界市場規模は2024年に121億7,000万米ドル、2030年には176億2,000万米ドルに達し、CAGR 6.56%で成長すると予測されています。

世界人口の高齢化に伴い、アルツハイマー病および関連する認知症の有病率は著しく上昇しており、より効果的な治療介入への需要が高まっています。市場は従来、コリンエステラーゼ阻害剤やNMDA受容体拮抗剤などの対症療法が牽引してきたが、神経科学の新たな進歩により、疾患修飾療法への道が開かれつつあります。これらの新しいアプローチは、βアミロイド斑やタウ蛋白質のもつれなど、この病気の生物学的メカニズムに対処することを目的としています。製薬会社や研究機関は、この方向に多額の投資を行っています。開発は進んでいるもの、疾患の複雑さや臨床試験での失敗率の高さにより、この分野は継続的なハードルに直面しており、医薬品開発や商業化への取り組みが引き続き課題となっています。

市場促進要因

ヘルスケア産業の成長

主な市場課題

治療とケアにかかるコストの高さ

主要市場動向

タウ標的治療薬の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の認知症・アルツハイマー病治療市場に与える影響

第5章 世界の認知症・アルツハイマー病治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤クラス別（コリン作動性/コリンエステラーゼ（ChE）阻害剤、メマンチン、配合薬、その他）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の認知症・アルツハイマー病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の認知症・アルツハイマー病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の認知症・アルツハイマー病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の認知症・アルツハイマー病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの認知症・アルツハイマー病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 混乱：紛争、パンデミック、貿易障壁

第14章 世界の認知症・アルツハイマー病治療市場：SWOT分析

第15章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第16章 競合情勢

• Merz Pharma GmbH & Co. KGaA
• Novartis AG
• Pfizer, Inc.
• Ono Pharmaceutical Co., Ltd.
• Johnson & Johnson Services, Inc.
• H. Lundbeck A/S
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• Eli Lilly and Company
• Corium, Inc.

第17章 戦略的提言

第18章 調査会社について・免責事項

The Global Dementia and Alzheimer's Disease Treatment Market was valued at USD 12.17 Billion in 2024 and is projected to reach USD 17.62 Billion by 2030, growing at a CAGR of 6.56%. As global populations age, the prevalence of Alzheimer's disease and related dementias is rising significantly, fueling demand for more effective therapeutic interventions. While the market has traditionally been driven by symptomatic treatments such as cholinesterase inhibitors and NMDA receptor antagonists, new advancements in neuroscience are now paving the way for disease-modifying therapies. These newer approaches aim to address the biological mechanisms of the disease, including beta-amyloid plaques and tau protein tangles. Pharmaceutical companies and research institutions are investing heavily in this direction. Despite the progress, the field faces ongoing hurdles due to the complexity of the disease and the high rate of failure in clinical trials, which continue to challenge drug development and commercialization efforts.

Key Market Drivers

Growth in Healthcare Industry

The continued expansion of the global healthcare industry-generating more than USD 4 trillion in annual revenues-serves as a major catalyst for growth in the dementia and Alzheimer's treatment market. Key contributors include pharmaceuticals and biotechnology, which together account for nearly USD 850 billion, and diagnostics and medical technology, generating over USD 400 billion. With improved life expectancy and better access to medical services, healthcare systems are increasingly prioritizing age-related neurodegenerative diseases. This trend is driving investment in research and development focused on Alzheimer's and dementia therapies, and is supported by growing global awareness and demand for effective long-term treatment options.

Key Market Challenges

High Cost of Treatment and Care

The elevated cost of treatment and associated care services represents a key barrier in the dementia and Alzheimer's disease treatment market. The financial strain extends beyond pharmaceutical expenditures, encompassing long-term care, specialized nursing, and daily assistance-all of which are typically not fully covered by public health insurance in many regions. The introduction of innovative disease-modifying therapies, while clinically promising, adds to cost concerns due to their complex production, monitoring requirements, and regulatory demands. These high costs challenge the affordability and accessibility of new treatments, particularly in low- and middle-income countries with constrained healthcare budgets and limited infrastructure for administering advanced therapeutics.

Key Market Trends

Advancement in Tau-Targeted Therapies

An important trend shaping the market is the increasing focus on tau-targeted therapies as an alternative or complement to amyloid-focused treatments. Research has shown that abnormal accumulation of tau proteins, which form neurofibrillary tangles in the brain, is closely associated with cognitive decline in Alzheimer's patients. As traditional therapies targeting amyloid plaques have delivered limited results, pharmaceutical companies are shifting attention toward tau as a therapeutic target. Innovations such as ACI-35-a liposome-based vaccine targeting phosphorylated tau-have shown promising safety and tolerability profiles in clinical trials. The pipeline now includes various modalities like monoclonal antibodies, antisense oligonucleotides, and small molecule inhibitors aimed at mitigating tau pathology. These advancements are expected to drive future breakthroughs in disease-modifying treatments.

Key Market Players

• Merz Pharma GmbH & Co. KGaA
• Novartis AG
• Pfizer, Inc.
• Ono Pharmaceutical Co., Ltd.
• Johnson & Johnson Services, Inc.
• H. Lundbeck A/S
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• Eli Lilly and Company
• Corium, Inc.

Report Scope

In this report, the Global Dementia and Alzheimer's Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dementia and Alzheimer's Disease Treatment Market, By Drug Class:

• Cholinergic/ Cholinesterase (ChE) Inhibitors
• Memantine
• Combination Drugs
• Others

Dementia and Alzheimer's Disease Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Dementia and Alzheimer's Disease Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dementia and Alzheimer's Disease Treatment Market.

Available Customizations:

Global Dementia and Alzheimer's Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Dementia and Alzheimer's Disease Treatment Market

5. Global Dementia and Alzheimer's Disease Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Cholinergic/ Cholinesterase (ChE) Inhibitors, Memantine, Combination Drugs, Others)
  • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Dementia and Alzheimer's Disease Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dementia and Alzheimer's Disease Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Mexico Dementia and Alzheimer's Disease Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Canada Dementia and Alzheimer's Disease Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Distribution Channel

7. Europe Dementia and Alzheimer's Disease Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Dementia and Alzheimer's Disease Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. Germany Dementia and Alzheimer's Disease Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. United Kingdom Dementia and Alzheimer's Disease Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Dementia and Alzheimer's Disease Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Dementia and Alzheimer's Disease Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Dementia and Alzheimer's Disease Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Dementia and Alzheimer's Disease Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. India Dementia and Alzheimer's Disease Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. South Korea Dementia and Alzheimer's Disease Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. Japan Dementia and Alzheimer's Disease Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. Australia Dementia and Alzheimer's Disease Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Distribution Channel

9. South America Dementia and Alzheimer's Disease Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Dementia and Alzheimer's Disease Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. Argentina Dementia and Alzheimer's Disease Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. Colombia Dementia and Alzheimer's Disease Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Dementia and Alzheimer's Disease Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Distribution Channel
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Dementia and Alzheimer's Disease Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Saudi Arabia Dementia and Alzheimer's Disease Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. UAE Dementia and Alzheimer's Disease Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Dementia and Alzheimer's Disease Treatment Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Merz Pharma GmbH & Co. KGaA
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Novartis AG
• 16.3. Pfizer, Inc.
• 16.4. Ono Pharmaceutical Co., Ltd.
• 16.5. Johnson & Johnson Services, Inc.
• 16.6. H. Lundbeck A/S
• 16.7. F. Hoffmann-La Roche Ltd.
• 16.8. AbbVie Inc.
• 16.9. Eli Lilly and Company
• 16.10. Corium, Inc.

17. Strategic Recommendations

18. About Us & Disclaimer